Evotec Financial Statements From 2010 to 2026
| EVO Stock | USD 3.68 0.05 1.38% |
Check Evotec SE financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evotec SE's main balance sheet or income statement drivers, such as , as well as many indicators such as . Evotec financial statements analysis is a perfect complement when working with Evotec SE Valuation or Volatility modules.
Check out the analysis of Evotec SE Correlation against competitors. Evotec SE ADR Company Operating Margin Analysis
Evotec SE's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Evotec SE Operating Margin | (0.27) % |
Most of Evotec SE's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evotec SE ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Evotec SE ADR has an Operating Margin of -0.266%. This is 99.24% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 95.17% lower than that of the firm.
Evotec SE ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evotec SE's current stock value. Our valuation model uses many indicators to compare Evotec SE value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evotec SE competition to find correlations between indicators driving Evotec SE's intrinsic value. More Info.Evotec SE ADR is rated # 5 in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evotec SE's earnings, one of the primary drivers of an investment's value.About Evotec SE Financial Statements
Evotec SE investors utilize fundamental indicators, such as revenue or net income, to predict how Evotec Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Evotec Se operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 4715 people.
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Evotec Stock
Moving against Evotec Stock
| 0.82 | TRV | The Travelers Companies | PairCorr |
| 0.79 | DD | Dupont De Nemours | PairCorr |
| 0.69 | JNJ | Johnson Johnson | PairCorr |
| 0.66 | PFE | Pfizer Inc | PairCorr |
| 0.65 | CUB | Lionheart Holdings | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Evotec SE Correlation against competitors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.